[Form 4] Quest Diagnostics Inc. Insider Trading Activity

Rhea-AI Filing Summary

Patrick Plewman, Senior Vice President for Diagnostic Services at Quest Diagnostics Inc. (DGX), reported a sale of 1,975 shares of Quest Diagnostics common stock on 08/15/2025 at a price of $180 per share. Following the reported sale, Mr. Plewman beneficially owns 17,244 shares, held directly. The filing notes the sale was effected pursuant to a Rule 10b5-1 sales plan. The Form 4 was executed on behalf of Mr. Plewman by an attorney-in-fact on 08/19/2025.

Positive

• Transaction disclosed under a Rule 10b5-1 plan, indicating a pre-established, rule-compliant sales arrangement
• Clear disclosure of post-transaction ownership (17,244 shares) and transaction details (date, price, amount)

Negative

• Insider sold 1,975 shares, reducing direct beneficial ownership
• Sale reported at $180 per share, which may be viewed negatively by some investors (factually reported)

Insights

Corporate Governance Expert

Insider disclosed a planned, rule-compliant sale reducing direct holdings; procedural transparency is evident.

The Form 4 shows a routine disposition of 1,975 shares at $180 each under a Rule 10b5-1 plan, which indicates the transaction followed a pre-established trading plan intended to provide an affirmative defense under insider trading rules. The remaining direct beneficial ownership of 17,244 shares is disclosed, and the form was signed by an attorney-in-fact. From a governance perspective, the filing meets Section 16(a) disclosure requirements and documents the compliance mechanism used for the sale.

Securities Compliance Analyst

Disclosure is complete for the reported transaction and cites the 10b5-1 plan; no regulatory red flags in the form itself.

The document lists transaction code S(1) for the sale on 08/15/2025, the per-share price of $180, and the post-transaction direct ownership figure. The explicit mention that the sale was effected pursuant to a Rule 10b5-1 plan signals adherence to an established trading plan; the signature by an attorney-in-fact is properly noted with a date. Based solely on the filing content, this is a routine, compliant insider sale disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plewman Patrick

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP for Diagnostic Services

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		S(1)		1,975	D	$180	17,244	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Remarks:

	Sean D. Mersten, Attorney in Fact for Patrick Plewman	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the Quest Diagnostics (DGX) insider report on Form 4?

The filing reports a sale of 1,975 Quest Diagnostics common shares on 08/15/2025 at $180 per share.

Who filed the Form 4 for DGX and what is their role?

The reporting person is Patrick Plewman, Senior Vice President for Diagnostic Services at Quest Diagnostics.

Was the sale covered by a 10b5-1 plan in the DGX Form 4?

Yes. The sale was effected pursuant to a Rule 10b5-1 sales plan, as stated in the filing.

How many Quest Diagnostics shares does the insider own after the sale?

Following the reported transaction, the insider beneficially owns 17,244 shares (direct ownership).

When was the Form 4 signed on behalf of the reporting person?

The Form 4 was signed by an attorney-in-fact on 08/19/2025.